Lundbeck’s drug portfolio faces patent expirations but shows growth potential. Find out why HLBBF stock could see upside with ...

Approximately $50.0 million of net revenue from sales of LUMRYZ estimated for the fourth quarter, a greater than 150% increase over $19.5 million for the comparable period in 2023 -- --2,500 patients ...

This is particularly true when it comes to technology and the current systems that most pharmaceutical companies deploy. Traditional sales software has been essentially a call reporting and ...

Investing.com - Novo Nordisk (CSE: NOVOb ) remains the "most exciting growth story" in the European pharmaceutical sector and ...

Lifecore Biomedical, Inc. beats earnings expectations. Reported EPS is $-0.25, expectations were $-0.27. Operator: Good ...

LUMRYZ, is an extended-release sodium oxybate medication approved by the FDA on May 1, 2023, as the first and only once-at-bedtime treatment for cataplexy or excessive daytime sleepiness (EDS) in ...

It is a newer concept for pharma ... for sales, marketing and patient communication materials, in print or digital form. It might encompass elements such as headlines, body copy, images, calls ...

"Sectors like chemicals, defence, renewables and electronics manufacturing services are poised for significant growth despite high valuations, led by scalability in business, in 2025," Satish Menon, ...

Alcoholic drinks like beer and wine should carry warnings of their links to cancer, the US’s top doctor said, citing a lack ...

BFA Law Notifies ASML Holding Investors with Losses of Upcoming January 13 Deadline and Urges You to Contact the Firm ...

Gautam Trivedi sees potential growth in FMCG, finance, IT, pharma, and renewable energy sectors. He notes the influence of ...

Novo Nordisk (NVO) and Eli Lilly's (LLY) weight loss drugs lead Evaluate Pharma’s list of best-selling drugs projected for ...